In addition, the company says the cells can be dose-adjusted or removed as needed. Sigilon has hired Bioverativ chief global therapeutics operations officer, Minerva Neurosciences , as CEO. Sigilon is poised to move its cell-based therapeutics implants to phase 1 trials, with a focus on diabetes, haemophilia and lysosomal storage disorders. Meanwhile, Sigilon Therapeutics is developing a "living therapeutics" platform that delivers therapeutic proteins inside the body via genetically engineered cells, using polymer capsules to hide the cells from the body's immune system for 2016 .
Sigilon has hired Bioverativ chief global therapeutics operations officer, Minerva Neurosciences , as CEO. Sigilon is poised to move its cell-based therapeutics implants to phase 1 trials, with a focus on diabetes, haemophilia and lysosomal storage disorders. Meanwhile, Sigilon Therapeutics is developing a "living therapeutics" platform that delivers therapeutic proteins inside the body via genetically engineered cells, using polymer capsules to hide the cells from the body's immune system for 2016 .